Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia

Journal of the National Cancer Institute

Volumn 95, Issue 20, 2003, Pages 1548-1551

  Offit, Kenneth ^a   Levran, Orna ^b   Mullaney, Brian ^c   Mah, Katherine ^a   Nafa, Khedoudja ^a   Batish, Sat Dev ^b   Diotti, Raffaella ^b   Scheider, Hildegard ^d   Deffenbaugh, Amie ^c   Scholl, Thomas ^c   Proud, Virginia K ^e   Robson, Mark ^a   Norton, Larry ^a   Ellis, Nathan ^a   Hanenberg, Helmut ^d   Auerbach, Arleen D ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Myriad Genetic Laboratories   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ARTICLE; BONE MARROW DISEASE; BRAIN TUMOR; BREAST CANCER; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FANCONI ANEMIA; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HUMAN; JEW; MALE; MEDULLOBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIGION; ALLELE; BREAST TUMOR; CHILD; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MUTATION; PEDIGREE; REGISTER; SYNDROME; TUMOR SUPPRESSOR GENE;

ALLELES; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; FANCONI ANEMIA; FEMALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; JEWS; MALE; MEDULLOBLASTOMA; PEDIGREE; REGISTRIES; SYNDROME;

EID: 0142054687     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg072     Document Type: Article

References (18)

1. Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective of the International Fanconi Anemia Registry (IFAR). Blood 2003;101: 1249-56.
2. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002;297:606-9.
3. Verlander PC, Kaporis A, Liu Q, Zhang Q, Seligsohn U, Auerbach AD. Carrier frequency of the IVS4 +4 A→T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood 1995;86:4034-8.
4. Giampietro PF, Adler-Brecher B, Verlander PC, Pavlakis SG, Davis JG, Auerbach AD. The need for more accurate and timely diagnosis in Fanconi anemia. A report from the International Fanconi Anemia Registry. Pediatrics 1993;91:1116-20.
5. Positional cloning of the Fanconi anaemia group A gene. The Fanconi Anemia/Breast Cancer Consortium. Nat Genet 1996;14: 324-8.
6. Hanenberg H, Batish SD, Pollok KE, Vieten L, Leurs C, Cooper RJ, et al. Phenotypic correction of primary T cells from patients with Fanconi anemia with retroviral vectors as a diagnostic tool. Exp Hematol 2002;30: 410-20.
7. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13:126-8.
8. Auerbach AD, Pujara K, Greenbaum J, Batish SD, Verlander PC, Levran O. Spectrum of sequence variation in the FANCG gene: an International Fanconi Anemia Registry (IFAR) study. Hum Mutat 2003;21:158-68.
9. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14: 188-90.
10. National Human Genome Research Institute (NHGRI). An open access on-line breast cancer mutation data base: an international collaborative effort hosted by NHGRI. Available at: http://research.nhgri.nih.gov/bic/. [Last accessed August 18, 2003.]
11. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. BRCA2 is required for embryonic cellular proliferation in the mouse. Genes Dev 1997;11:1242-52.
12. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
13. Kauff ND, Perez-Segura P, Robson ME, Scheuer L, Siegel B, Schluger A, et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002; 39:611-4.
14. Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, et al. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 1997;60: 1242-6.
15. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 1999;91:1310-6.
16. de Chadarevian JP, Vekemans M, Bernstein M. Fanconi's anemia, medulloblastoma, Wilms' tumor, horseshoe kidney, and gonadal dysgenesis. Arch Pathol Lab Med 1985;109:367-9.
17. Ruud E, Wesenberg F. Microcephalus, medulloblastoma and excessive toxicity from chemotherapy: an unusual presentation of Fanconi anaemia. Acta Paediatr 2001;90: 580-3.
18. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.